The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer
The Oncologist · 04.11.2024 · 29 (11) · e1532-e1539
DOI: 10.1093/oncolo/oyae201 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 07.09.2024. Verfasst von Luke Steventon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department and Centre of Medicines Optimization Research and Education (CMORE), University College Hospitals NHS Foundation Trust, 2…. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Research for Patient Benefit.
Abstract (Originalsprache)
Introduction
Chemotherapy forms the cornerstone of systemic treatment for advanced ovarian cancer, extending overall survival; however, drug-related toxicity can lead to treatment delays, potentially diminishing treatment efficacy. This study evaluated the impact of treatment delays on all-cause mortality of patients with ovarian cancer, to better inform decisions on patient management.
Methods
This retrospective, population-based cohort study included 1517 women with advanced-stage ovarian cancer, receiving first-line adjuvant or neoadjuvant chemotherapy in 2014 and 2015. The frequency of inter-cycle delays >7 days was calculated using drug administration dates. Kaplan-Meier estimates were used to compare 2-year overall survival (OS) between patients who were delayed and those treated to schedule. Cox proportional hazards regression was used to investigate the impact of treatment delay on all-cause mortality. Inverse probability of treatment weighting propensity scores were used to adjust for confounding variables.
Results
Delays >7 days occurred in 35.3% of patients. Two-year OS probability was 62.7% in patients who experienced treatment delays >7 days (95% CI, 58.7-66.9) compared to 69.1% in those treated to schedule (95% CI, 66.2-72.0). Delays were not significantly associated with all-cause mortality when adjusted for confounders (HR 1.00 95% CI, 0.83-1.20, P = .9).
Conclusions
Delays to chemotherapy treatment were not significantly associated with worsened survival in patients with advanced-stage ovarian cancer. These results can inform clinical decision making that prioritize toxicity management and quality of life for those treated with chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department and Centre of Medicines Optimization Research and Education (CMORE), University College Hospitals NHS Foundation Trust, 235 Euston rd, London NW1 2PP, United Kingdom.
- Department of Practice and Policy, UCL School of Pharmacy, London WC1H 9JP, United Kingdom.
- UCL Cancer Institute, Department of Oncology, London WC1 6DD, United Kingdom.
- School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- The Royal Marsden NHS Trust, London SW3 6JJ, United Kingdom.
- National Disease Registration Service (NDRS), NHS England, London E14 4PU, United Kingdom.
ORCID-Profile: Luke Steventon, Kenneth K C Man, Shibani Nicum, Rowan E Miller, Shira Peleg Hasson, Emma Kipps, Pinkie Chambers
Förderung
- National Institute for Health and Care Research
- Research for Patient Benefit
Zitieren
APA
Steventon, L., Man, K. K. C., Nicum, S., Miller, R. E., Peleg Hasson, S., Shah, S., Baser, M., Kipps, E., Forster, M. D., Almossawi, O., & Chambers, P. (2024). The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer. The Oncologist, 29(11), e1532-e1539. https://doi.org/10.1093/oncolo/oyae201
Vancouver
Steventon L, Man KKC, Nicum S, Miller RE, Peleg Hasson S, Shah S, et al. The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer. The Oncologist. 2024;29(11):e1532-e1539. doi:10.1093/oncolo/oyae201
BibTeX
@article{Steventon2024,
author = {Steventon, Luke and Man, Kenneth K C and Nicum, Shibani and Miller, Rowan E and Peleg Hasson, Shira and Shah, Samixa and Baser, Michael and Kipps, Emma and Forster, Martin D and Almossawi, Ofran and Chambers, Pinkie},
title = {The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {11},
pages = {e1532--e1539},
doi = {10.1093/oncolo/oyae201}
}
EUVIMED